Mural Oncology (MURA) Competitors $2.08 -0.01 (-0.48%) Closing price 04:00 PM EasternExtended Trading$2.08 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MURA vs. KLRS, BTMD, ZYBT, ONCY, ANIX, ATOS, VIRI, CGTX, HURA, and SCLXShould you be buying Mural Oncology stock or one of its competitors? The main competitors of Mural Oncology include Kalaris Therapeutics (KLRS), biote (BTMD), Zhengye Biotechnology (ZYBT), Oncolytics Biotech (ONCY), Anixa Biosciences (ANIX), Atossa Genetics (ATOS), Virios Therapeutics (VIRI), Cognition Therapeutics (CGTX), TuHURA Biosciences (HURA), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry. Mural Oncology vs. Its Competitors Kalaris Therapeutics biote Zhengye Biotechnology Oncolytics Biotech Anixa Biosciences Atossa Genetics Virios Therapeutics Cognition Therapeutics TuHURA Biosciences Scilex Kalaris Therapeutics (NASDAQ:KLRS) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Do analysts recommend KLRS or MURA? Kalaris Therapeutics currently has a consensus price target of $3.00, suggesting a potential downside of 39.15%. Mural Oncology has a consensus price target of $12.00, suggesting a potential upside of 476.92%. Given Mural Oncology's higher possible upside, analysts clearly believe Mural Oncology is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33Mural Oncology 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media favor KLRS or MURA? In the previous week, Kalaris Therapeutics had 2 more articles in the media than Mural Oncology. MarketBeat recorded 4 mentions for Kalaris Therapeutics and 2 mentions for Mural Oncology. Mural Oncology's average media sentiment score of 0.95 beat Kalaris Therapeutics' score of 0.79 indicating that Mural Oncology is being referred to more favorably in the news media. Company Overall Sentiment Kalaris Therapeutics Positive Mural Oncology Positive Do institutionals & insiders hold more shares of KLRS or MURA? 66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 80.2% of Mural Oncology shares are owned by institutional investors. 75.0% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 2.2% of Mural Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable valuation and earnings, KLRS or MURA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalaris TherapeuticsN/AN/A-$58.77MN/AN/AMural OncologyN/AN/A-$128.51M-$8.59-0.24 Which has more risk and volatility, KLRS or MURA? Kalaris Therapeutics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 2.93, meaning that its share price is 193% more volatile than the S&P 500. Is KLRS or MURA more profitable? Kalaris Therapeutics' return on equity of -81.02% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Kalaris TherapeuticsN/A -81.02% -65.15% Mural Oncology N/A -107.76%-87.57% SummaryKalaris Therapeutics beats Mural Oncology on 7 of the 12 factors compared between the two stocks. Get Mural Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for MURA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MURA vs. The Competition Export to ExcelMetricMural OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.05M$2.62B$6.05B$10.51BDividend YieldN/A57.77%5.73%4.80%P/E Ratio-0.2422.7985.4427.36Price / SalesN/A557.62516.11196.40Price / CashN/A174.0137.5761.53Price / Book0.255.5112.426.82Net Income-$128.51M$33.06M$3.32B$276.89M7 Day PerformanceN/A0.95%1.01%0.27%1 Month Performance0.48%14.25%10.75%8.31%1 Year Performance-39.71%0.85%76.19%35.60% Mural Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MURAMural Oncology3.3336 of 5 stars$2.08-0.5%$12.00+476.9%-39.1%$36.05MN/A-0.24119KLRSKalaris Therapeutics1.3571 of 5 stars$7.72-3.9%$3.00-61.1%N/A$144.38MN/A0.00110News CoverageHigh Trading VolumeBTMDbiote2.3476 of 5 stars$2.84-2.4%$6.00+111.3%-45.6%$140.41M$197.19M3.16194ZYBTZhengye BiotechnologyN/A$2.94+2.1%N/AN/A$138.68M$25.53M0.00278News CoverageAnalyst ForecastONCYOncolytics Biotech1.9247 of 5 stars$1.35-0.7%$5.00+270.4%+5.2%$135.49MN/A-5.0030ANIXAnixa Biosciences2.8529 of 5 stars$4.11+26.5%$9.00+119.0%+42.0%$135.29MN/A-11.745News CoverageAnalyst ForecastHigh Trading VolumeATOSAtossa Genetics2.5998 of 5 stars$1.01+1.0%$6.25+518.8%-27.5%$130.46MN/A-4.398News CoverageAnalyst DowngradeVIRIVirios TherapeuticsN/A$6.69+4.4%$5.00-25.3%+50.0%$128.84MN/A-24.785News CoverageGap DownCGTXCognition Therapeutics2.6012 of 5 stars$1.75+13.6%$2.83+61.9%+308.1%$128.66MN/A-2.6120Positive NewsHURATuHURA Biosciences1.6635 of 5 stars$2.50+0.4%$12.67+406.7%N/A$127.75MN/A0.00N/ASCLXScilex2.2239 of 5 stars$18.23+8.4%$455.00+2,395.9%-47.1%$126.88M$56.59M-0.6380High Trading Volume Related Companies and Tools Related Companies Kalaris Therapeutics Competitors biote Competitors Zhengye Biotechnology Competitors Oncolytics Biotech Competitors Anixa Biosciences Competitors Atossa Genetics Competitors Virios Therapeutics Competitors Cognition Therapeutics Competitors TuHURA Biosciences Competitors Scilex Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MURA) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
